GLP-1 receptor agonists are an emerging research focus for metabolic and inflammatory pathways in Parkinson's disease
GLP-1 receptor agonists show promise for Parkinson's disease research
This bibliometric analysis of 282 articles identifies GLP-1 receptor agonists as a growing research area for Parkinson's disease. Key themes…
New research highlights how GLP-1 medications, often used for metabolic issues, are becoming a major focus in treating Parkinson's disease.
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression
Shared Molecular Pathways Link Endocrine Disorders and Periodontitis
This narrative review synthesizes the molecular mechanisms underlying the crosstalk between endocrine disorders and periodntis. It identifie…
New research identifies shared biological pathways that link endocrine disorders with gum disease, potentially changing how doctors treat bo…
GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
GLP-1 drugs help heart failure with preserved ejection fraction
This meta-analysis of 11,234 patients with heart failure (HFpEF and HFrEF) found that GLP-1 receptor agonists significantly reduced HF worse…
GLP-1 receptor agonists improve outcomes in heart failure with preserved ejection fraction but not in reduced ejection fraction, according t…
Dextrins may increase circulating GLP-1 concentrations and satiety in adults with limited evidence certainty
Specific dietary fibers may support GLP-1 levels in adults
This scoping review of 52 studies involving 1,085 participants examined the effects of specific dietary fibers on GLP-1 levels and satiety. …
Certain types of dietary fiber, like dextrins, show promise in increasing GLP-1 levels and helping people feel full.
Oral small-molecule GLP-1RAs reduce body weight by 3.93 and HbA1c by 0.94
Oral GLP-1 medications help manage weight and blood sugar
This meta-analysis evaluates the efficacy and safety of oral small-molecule GLP-1RAs in adults with Type 2 Diabetes and obesity. The analysi…
New data shows oral versions of GLP-1 drugs can lower body weight and blood sugar for people with type 2 diabetes or obesity.
Gut microbiota may influence metabolic response to GLP-1 receptor agonists in obesity and type 2 diabetes
Gut bacteria may influence how people respond to weight loss drugs
This narrative review explores how gut microbial communities and metabolite profiles potentially determine patient responses to GLP-1 recept…
New research suggests that the unique makeup of your gut bacteria could play a role in how well you respond to GLP-1 medications.
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Elecoglipron results in 40.4% to 88.8% of patients reaching at least 5% weight loss
Trial shows weight loss in adults with obesity using elecoglipron
This Phase 2 randomized controlled trial evaluated elecoglipron in 310 adults with obesity or overweight and a weight-related condition. Par…
A new clinical trial shows that the medication elecoglipron helps people with obesity lose a significant amount of body weight.
All GLP-1 receptor agonists Articles
- GLP-1 receptor agonists are an emerging research focus for metabolic and inflammatory pathways in Parkinson's disease
- SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
- Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
- GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
- Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
- Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression
- Dextrins may increase circulating GLP-1 concentrations and satiety in adults with limited evidence certainty
- GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
- Oral small-molecule GLP-1RAs reduce body weight by 3.93 and HbA1c by 0.94
- Gut microbiota may influence metabolic response to GLP-1 receptor agonists in obesity and type 2 diabetes
- General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
- Elecoglipron results in 40.4% to 88.8% of patients reaching at least 5% weight loss
- GLP-1R exposure shows no causal link to most mental disorders except eating disorders
- Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
- GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia
- Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
- GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
- GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
- GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain
- Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
- Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
- Bariatric surgery yields greater long-term weight loss than GLP-1 receptor agonists in adults with obesity
- GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
- GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
- Genetic analysis links GLP-1 agonism to pancreatitis risk and sarcopenia in large cohorts
- Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
- Meta-analysis of Mendelian randomization suggests GLP-1 receptor agonism lowers vascular dementia risk
- Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefit
- GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
- Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
- Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
- GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
- Narrative review examines multidisciplinary strategies for metabolic syndrome in bipolar disorder
- Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
- GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
- Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
- Network meta-analysis finds metabolic surgery superior to GLP-1 agonists for weight loss in obesity
- GLP-1 agents and cognitive interventions address obesity and eating disorders via appetite and gut-brain signaling pathways
- Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
- Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
- HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes
- GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
- FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
- Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease